UR Medicine's Wilmot Cancer Institute | Strategic Alliance Partners

The University of Rochester’s Wilmot Cancer Institute provides world-class cancer care and conducts pivotal cancer research. The goal is to prevent and conquer cancer through innovation in science, patient care, education, and community outreach. Serving a 27-county area in upstate New York, Wilmot features an 87-bed flagship cancer center, 13 outpatient locations, one of New York state’s largest bone marrow transplant programs and more.

Connect with us:

Latest from UR Medicine's Wilmot Cancer Institute

How the Drive to Connect the Oncology Community Built an Educational Podcast Platform: With D. Ross Camidge, MD, PhD; and Rahul Gosain, MD, MBA

November 20, 2024

Podcast

Drs Camidge and Gosain discuss how Dr Gosain harnessed social media to create a podcast with practice updates for up-and-coming oncology professionals.

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

November 14, 2024

Video

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Dr. O'Regan on the RIGHT Choice Trial in HR+/HER2- Breast Cancer

March 21, 2023

Video

Ruth M. O’Regan, MD, discusses how results from the phase 2 RIGHT Choice trial could influence the treatment paradigm in hormone receptor–positive, HER2-negative breast cancer.

Dr. Falkson on the Use of Sacituzumab Govitecan in HR+/HER2- Breast Cancer

February 07, 2023

Video

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

Accuracy of Sentinel Lymph Node Biopsies Are Vital to Inform Treatment Decisions in Breast Cancer

January 27, 2023

Article

The evolving treatment landscape across breast cancer has escalated the need for the accuracy of sentinel lymph node biopsies following treatment with neoadjuvant chemotherapy to correctly inform subsequent treatment decisions for patients.

Dr. O’Regan on the Development of Oral SERDs in Breast Cancer

August 09, 2022

Video

Ruth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.

ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen

February 21, 2022

Video

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

February 18, 2022

Video

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Personalized Medicine Shows Extended Reach Throughout Breast Cancer

November 18, 2021

Article

Molecular markers, risk, and response are being used to better tailor escalated and de-escalated treatment approaches for women with breast cancer.

Dr. Falkson on the Potential to De-Escalate Chemotherapy in HER2+ Breast Cancer

November 12, 2021

Video

Carla Falkson, MBChB, MMed, MD, discusses the potential to de-escalate chemotherapy in HER2-positive breast cancer.

Dr. Barr on the Implications of the Long-Term Results of the RESONATE-2 Trial in CLL

July 15, 2021

Video

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Barr on the Rationale for the Long-Term Evaluation of the RESONATE-2 Trial in CLL

June 30, 2021

Video

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Barr on the Next Steps of the RESONATE-2 Trial in CLL

June 11, 2021

Video

Paul M. Barr, MD, discusses the next steps of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

ACCC Tool Gives Individualized Guidance for Geriatric Assessment Implementation in Patients With Cancer

June 02, 2021

Article

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.